MAP2K1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, we demonstrated that overexpression of MOS and TPL2 is associated with BCR::ABL1‐independent dasatinib resistance in CML cells and that inhibition of MOS and TPL2 or ERK1/2 activation by MEK1/2 inhibitor overcomes dasatinib resistance (Figure 5).